A.R.T. Advisors’s Adverum Biotechnologies ADVM Stock Holding History

A.R.T. Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,737	Closed	-$91K	–	1318
2019 Q1	$91K	Buy	+1,737	New	+$70.2K	0.01%	1182
2017 Q3	–	Sell	-3,366	Closed	-$84K	–	1314
2017 Q2	$84K	Buy	3,366 +1,590	+90%	+$43.5K	﹤0.01%	1267
2017 Q1	$47K	Buy	+1,776	New	+$50.5K	﹤0.01%	1329
2016 Q3	–	Sell	-2,054	Closed	-$64K	–	626
2016 Q2	$64K	Sell	2,054 -7,306	-78%	-$330K	﹤0.01%	1253
2016 Q1	$483K	Buy	+9,360	New	+$523K	0.02%	871
2015 Q4	–	Sell	-17,120	Closed	-$1.41M	–	1434
2015 Q3	$1.41M	Buy	17,120 +7,093	+71%	+$906K	0.05%	507
2015 Q2	$1.63M	Buy	+10,027	New	+$3.38M	0.05%	541
2015 Q1	–	Sell	-552	Closed	-$298K	–	1396
2014 Q4	$298K	Buy	+552	New	+$213K	0.01%	1103

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

A.R.T. Advisors's ADVM Position: Q2 2019 in Review

A.R.T. Advisors sold out of Adverum Biotechnologies (ADVM) in Q2 2019, closing a stake of 1,737 shares — an estimated $91K sold.

A.R.T. Advisors first reported a position in ADVM in Q4 2014 and held it in 8 quarters. The position peaked at $1.63M in Q2 2015. 94 funds tracked by Wall St. Rank hold ADVM as of Q2 2019.

A.R.T. Advisors reported no remaining Adverum Biotechnologies position as of Q2 2019 after selling out during the quarter.
A.R.T. Advisors sold 1,737 Adverum Biotechnologies shares in Q2 2019, an estimated $91K.
A.R.T. Advisors first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 8 quarters.
A.R.T. Advisors's Adverum Biotechnologies position peaked at $1.63M in Q2 2015.
94 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.